Skip to content
Search

Latest Stories

US tech firm Palantir wins NHS Data Platform contract

US tech firm Palantir wins NHS Data Platform contract

The contract award will see investment of up to £330m over the course of seven years

NHS England is set to introduce a new tool from spring next year to improve care for millions of patients, tackle waiting lists and reduce hospital discharge delays.


The new tool, known as the Federated Data Platform, will bring together key information currently held in separate NHS systems such as the number of beds in a hospital, the size of elective waiting lists, staff rosters, the availability of medical supplies and social care places.

The contract to provide the software has been awarded to US data analytics giant Palantir, with support from Accenture, PwC, NECS and Carnall Farrar.

Over the contractual period of seven years, the NHS will be investing up to £330m in the  data platform and associated services.

In the first contract year, investment is expected to be at least £25.6m, NHSE confirmed on Tuesday (21 November).

Announcing the contract, NHS National Director for Transformation Dr Vin Diwakar said: “Better use of data is essential for the NHS to tackle waiting times, join up patient care and make the health service sustainable for the future.

“Patients come to the NHS at some of the most vulnerable points in their lives, and they want to know that our healthcare teams have access to the best possible information when it comes to their treatment and care.

“This new tool provides a safe and secure environment to bring together data, which enables us to develop and deliver more responsive services for patients and will help the health service drive the recovery in elective care.”

Palantir CEO Alex Karp said that their software can integrate complex, sensitive data in a way that “protects security, respects privacy and puts the customer in full control.”

The NHS also ensured that no company involved in the Federated Data Platform can access health and care data without its permission.

“All data within the platform is under the control of the NHS and will only be used for direct care and planning. It will not be used to access data for research purposes and GP data will not feed into the national version of the software platform,” it said.

Every hospital trust and local health system will have their own version of the software, which enables them to connect and share information between them.

North Tees and Hartlepool Trust, where the system was introduced under pilot projects, has been able to reduce long term stays (21 days or more) by 36 per cent despite increased demand, with 7.7 per cent more patients being admitted to the hospital.

NHSE noted that the new Federated Data Platform builds on the success of the current National Data Platform, for which the contract is about to come to an end.

It will be the first use case in the NHS of Privacy Enhancing Technology (NHS-PET), a nationally assured and funded privacy tool to benefit all NHS organisations.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less